Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 68 (9), 688-90

Safety and Feasibility of Long-Term Temozolomide Treatment in Patients With High-Grade Glioma

Affiliations
Clinical Trial

Safety and Feasibility of Long-Term Temozolomide Treatment in Patients With High-Grade Glioma

P Hau et al. Neurology.

Abstract

We surveyed neuro-oncologists regarding patients treated with temozolomide for at least 12 cycles or 12 months. Patients receiving first-line temozolomide for a median 13 cycles had a median progression-free survival (PFS) of 14 months. Patients with recurrent disease receiving a median 14 cycles had a median PFS of 15.5 months. A small percentage of patients experienced grade III to IV toxicity. These results suggest that long-term treatment with temozolomide is feasible and well tolerated.

Similar articles

See all similar articles

Cited by 30 PubMed Central articles

See all "Cited by" articles

Publication types

MeSH terms

Feedback